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ABSTRACT
Chinese patent law has a short history whereas the United States ("U.S.") system has a more robust
history. This article chronicles important remaining differences between Chinese and U.S. patent
laws including the utility model successfully employed at State Intellectual Property Office of the
People's Republic of China ("SIPO") and in the Chinese courts, but not available under U.S. law.
Some differences are discussed in regard of patent appeals, reexaminations for invalidity, China's
lack of a reissue process to correct major errors, China's inventors remuneration process and
compulsory licensing of patents, and China's unique requirement of post termination compensation
to support a covenant not to compete. This article further discusses recent changes in U.S. Patent
law, as a result of the American Invents Act, that have no counterpart in China. This includes a
discussion on changes in the rules governing when prior art applies against applications, new
misjoinder rules and elimination of qui tam patent suits rules. This article discusses the new
procedure in the United States Patent and Trademark Office ("USPTO") called post grant review
and a companion process for review of validity of granted patents called inter partes review. These
new proceedings have the potential for invalidation of patents in a manner far less expensive than in
court. However, the devil will be in the details of the regulations and fees yet to be promulgated by
the USPTO or reviewed by the public. Whether China or the United States got it right is too early to
tell and is anyone's guess.

Copyright C 2012 The John Marshall Law School

Cite as Wayne C. Jaeschke, Zhun Lu & Paul Crawford, Comparison of Chinese and U.S.
Patent Reform Legislation: Which, If Either, Got it Right?,
11 J. MARSHALL REV. INTELL. PROP. L. 567 (2012).

COMPARISON OF CHINESE AND U.S. PATENT REFORM LEGISLATION:
WHICH, IF EITHER, GOT IT RIGHT?
WAYNE C. JAESCHKE, ZHUN Lu & PAUL CRAWFORD

INTRODUCTION.............................................................569

I. A HISTORICAL PERSPECTIVE ON CHINESE AND AMERICAN IP LAWS..
............ 570
A. China's Aggressive Patent Law Reform in 2008.......................... 570
B. The U.S. Patent Law has Developed by Legislation and Litigation.............. 570
C. The United States Abandoned its Longstanding "First-to-Invent" System
in2011.......................................................572
D. Echoes of Chinese Patent Philosophy in AIA..................................574
II.THE SINO-AMERICAN PATENT LAW DIVIDE
......................
.........
575
A. Chinese Utility Model Patents can Lead to Swift Justice...............575
B. Patent Application Filing and Prosecution in China and the United
States.....................
............................. ....576
1. Many Similarities Between the Practices.............
........... 576
2. Differences in Patent Eligible Subject Matter....................577
3. Chinese Applications are Not Automatically Examined by SIPO..........578
4. Applicants in the United States Must Submit Known Prior Art
References but the Chinese Practice is Less Clear .................
578
5. Post Application Data is Not Accepted in China .......................
578
6. "Best Mode"......................................
......... 579
a. Continuation Applications are Permitted at the USPTO but
Not SIPO.
....................................
......... 580
C. The Patent Appeals Process in China and the United States................580
D. Reexamination for Invalidity
..........................................
581
E. The Chinese System has No Equivalent to U.S. Reissue Proceedings to
Correct Major Patent Defects.
............................
........ 582
F. Beware of the Chinese P.R.B.'s Ex Officio Powers..........................582
G. Litigation in China
.................................................
582
H. Third Party Submission of References and Comments is Prevalent in
China; U.S. Applicants Are Wary of "Estoppel".............
......... 586
I. Unlike the United States, China Requires Inventor's Remuneration............587
J. Novelty Rules Differ in China and the United States, but will be Aligned
Under AIA............................................
....... 587
K. Non-Obvious Subject Matter is Required in the United States and China .. 588
L. Business Methods are Patentable in the United States, while a Three
Part Technical Test is Applied in China to Assess Patentability.............589
M. China has Compulsory License Provisions which are Strongly Opposed
in the United States...............................................590
N. AIA Provides Meaningful Prior User Rights in the United States for the
First Time
.................................
590
0. Security Reviews Differ in China Versus the United States...........591

567

[11:567 2012] The John Marshall Review of Intellectual Property Law

568

P. China's Employment Laws Govern some Trade Secret and Non-Compete
Issues Concerning Intellectual Property.
.....................
....... 592
. . . . . . . . .. . . . . . . . . . . . . . .
.... . . .
III. WHAT DOES AIA PORTEND FOR THE FUTURE?.
593
A. Grace Periods have been Altered, Increasing the Risk of
Commercialization Prior to Filing a Patent..
....................... 593
B. AIA Narrows the Application of Certain Other Types of Prior Art
Benefiting Commerce...............................................
594
C. New Misjoinder Provisions of the AIA
...................................
594
D. Under AIA, Novelty will be Defeated by International Public Use or Sale .. 595
E. Unlike Interference Proceedings, Derivation Proceedings will Survive
Under AIA............................................
....... 595
F. AIA Preserves Patent Term Extension Provisions....................596
G. Qui Tam and Marking Changes in AIA..
............................... 596
H. New Post Grant Proceedings in the United States....................598

IV. CONCLUSION................................................

...........

599

[11:567 2012]Comparison of Chinese and U.S. Patent Reform Legislation:
Which, If Either, Got it Right?

569

COMPARISON OF CHINESE AND U.S. PATENT REFORM LEGISLATION:
WHICH, IF EITHER, GOT IT RIGHT?
WAYNE C. JAESCHKE, ZHUN Lu & PAUL CRAWFORD*

INTRODUCTION

While business bumps along in the United States ("U.S."), the sleeping giant of
the twentieth century is now wide awake and threatens to outpace the U.S. in
innovation and patenting in the twenty-first century. The People's Republic of China
("China") has announced goals that would allow it to overtake the U.S. in numbers of
patents by 2015 or earlier.' China has invested heavily in new technology centers to
foster patentable innovations. 2 Renewable energy, including wind and solar, energy
storage batteries, semiconductors, wireless devices and biotechnology are at the head
of China's list. 3
In this article, the authors hope to illuminate some of the major historical
differences between the patent systems of the U.S. and China and explain how the
systems are evolving under recent patent reform legislation in each country. Part I
presents the relevant background of the Chinese and U.S. intellectual property ("IP")
laws. Part II discusses key differences, in theory and practice, between the two
systems. Finally, Part III looks to the future and what the recent patent law reform
will actually mean for those seeking patents in the U.S. and China.
*C Wayne C. Jaeschke, Zhun Lu & Paul Crawford 2012. The authors extend special thanks to
Geoff Zelley for his assistance with the Qui Tam section of this article and to Julia Figurelli-Masucci
for her project supervision and assistance with editing.
Paul E. Crawford is a partner in the Intellectual Property Group at Connolly Bove Lodge &
Hutz LLP. He represents clients in a variety of intellectual property areas including due diligence,
client counseling, licensing, patent interferences, litigation, prosecution, unfair competition and
trade secret law. He has litigated and arbitrated disputes ranging from protection of trade dress on
packaging of consumer paper products to obtaining injunctive relief against misappropriators of
complex chemical formulas for high performance automotive paint pigments.
Wayne C. Jaeschke is Of Counsel in the Intellectual Property Group at Connolly Bove Lodge &
Hutz LLP. He represents clients in a variety of areas including patent counseling and opinions, due
diligence, licensing and transactions, litigation, prosecution and reissue and reexaminations in
chemical related matters. Based on his business and environmental management experience, he
represents clients in business agreements especially for the transfer of goods and technology as well
as employment matters internationally.
Zhun Lu, Ph.D., is a Partner in the Intellectual Property Group at Connolly Bove Lodge &
Hutz LLP. Zhun is also the Director of the firm's Asian Pacific Practice. He represents clients in a
variety of areas including patent counseling, opinions, litigation, and prosecution primarily in the
biotech, biomedical, pharmaceutical, chemical, telecommunication, computer, and semiconductor
areas. He also advises clients on corporate matters relating to IP management.
1Rachel Griffith & Helen Miller, Innovation in China: The Risie of Chinese Inventors in the
Production of Knowledge 3 (Institute for Fiscal Studies, Working Paper No. W11/15, 2011).
2 See Ester H. Lim, Adding IP Fuel to China's Fire of Innovation, FINNEGAN (Apr. 16, 2010),
http://www.finnegan.com/resources/articles/articlesdetail.aspx?news f74e857c-76fb-410a-978acl9107546cbe.
3Steve Lohr, When Innovation, Too, Is Made in China, N.Y. TIMES, Jan. 2, 2011, at BU3.
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I. A HISTORICAL PERSPECTIVE ON CHINESE AND AMERICAN IP LAWS

A. China's Aggressive Patent Law Reform in 2008
China, in 2008, enacted its third and most aggressive amendment to its patent
laws. 4 Implementing regulations, which contain many of the "how to" instructions
for patent-practitioners, came into force February 1, 2010.5 These regulations are
equivalent to the U.S. rules of practice in chapter 37 of the U.S. Code of Federal
Regulations ("C.F.R"). 6 China's Guidelines for Patent Examination also became
effective in February of 2010.7 These Guidelines are equivalent to the U.S. Manual
of Patent Examination Procedure ("MPEP"). Unlike the U.S. case-by-case approach,
China's system of judicial interpretation is a synthesis of rules derived from judgemade law, legislation and concepts of the Supreme Court judges.
In contrast to the United States, which has patent legislation drawing its origin
in the American Revolution and the Constitution in the late 1700s, 8 China's first
patent law was enacted in 1985, quickly followed by first and second amendments in
1992 and 2000.9

B. The U.S. Patent Law has Developed by Legislation and Litigation
The U.S. patent landscape has tracked the development of technology from the
light bulb and steam engine to genetic engineering, semiconductors, rockets for outer
space, nanotechnology for ultra-small inner space, biotechnology, financial and other
business methods, and the world of the internet.
Providing legal support to
encompass such a wide expanse of technology has been a challenge. However, U.S.
Congress and especially U.S. courts have managed to fashion rules and remedies to
accommodate and support beneficial commercialization of such innovation.

4 Patent Law of the People's Republic of China (promulgated by the Standing Comm'n Nat'1
People's Cong., Dec. 27, 2008, effective Oct. 1, 2009) [hereinafter Chinese Patent Law]. For English
translation of the amended Chinese patent law, see EU-CHINA PROJECT ON THE PROTECTION OF
INTELLECTUAL PROPERTY RIGHTS, THIRD REV. OF CHINA'S PATENT LAW:
LEGAL TEXTS AND
DOCUMENTS ON THE DRAFTING PROCESS 2006-2008 (IPR2 2009) [hereinafter THIRD REV. OF CHINA'S
PATENT LAW], available at http://www.ipr2.org/images/eu-patentlaw-final.pdf.
5 Implementing Regulations of the Patent Law of the People's Republic of China (promulgated
by
the
St.
Council,
June
15,
2001,
amended
Jan.
9,
2010)
(China),
http://www.sipo.gov.cn/sipoEnglish2008/laws/lawsregulations/200804/t20080416_380326.html
[hereinafter Implementing Regulations].
6 See Ruay L. Ho, Priority Claim Differences Between China and the US, IP FORTUNE L.L.C.,
(Nov.
3
2007),

http://www.intelproplaw.com/Articles/files/Priority%/20Claim%/20Differences%/20between%/20China
%20and%20the%20US.pdf.
7 Guidelines for Patent Examination (promulgated by the St. Intell. Prop. Off., Jan. 21, 2010,
effective Feb. 1, 2010) (China) [hereinafter SIPO Guidelines].
8 See Bilski v. Kappos, 130 S.Ct. 3218, 3242 (2010).
9THIRD REV. OF CHINA'S PATENT LAW, supra note 4, at 1.
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The Founders wrote the basis of the U.S. patent system into the Constitution.1 0
They intended to promote the sciences and the useful arts by granting limited
monopolies to authors and inventors for public disclosure of their respective writings
and discoveries." Thomas Jefferson, as quoted by the Supreme Court in Diamond v.
Chakrabarty,1 2 wrote that "[i]ngenuity should receive a liberal encouragement," 13
Abraham Lincoln said that the patent system was one of the most important
developments in world history next to the printing press and the discovery of
America.14
The U.S. patent statutes were revised three times in the nineteenth century.15
The law was recodified and updated in 1952 when Congress added the last sentence
of section 103 of the U.S. Patent Act ("section 103") which states that "[p]atentability
shall not be negatived by the manner in which the invention was made." 16 This
clarified that a flash of genius is not necessary to have a patentable invention as
some earlier case law had suggested;1 7 at the same time the revised language
recognized that many new inventions were being made in corporate laboratories by
the interaction of several scientists and no longer in kitchens or garages where a
single bright inspiration gave rise to a new product.
As an example of the flexibility of the Courts in regard to changing technologies,
in Diamond, the Supreme Court held that microorganisms produced by genetic
engineering are not excluded from patent eligible subject matter. 18 This ruling was
made over the strong resistance of the United States Patent and Trademark Office
("USPTO"), which contended that such an innovation did not come within any of the
statutory classes of the 1952 Act. 19 The Court cited Congressional committee reports
that Congress intended to "include anything under the sun that is made by man" as
patentable subject matter. 20 Subject matter which is not eligible for patenting in the
United States includes laws of nature and newly discovered elements unchanged by
man. As a result, bacteria containing genes altered by human endeavor may be
patentable even though the subject matter is a living organism. The Harvard mouse
is an example of patentable living subject matter since the mouse is a result of manmade genetic manipulation. 21

10U.S. CONST. art. I,

§ 8, cl.

8.

11 Id.

12Diamond v. Chakrabarty, 447 U.S. 303 (1980).
13Id. at 308.
14Jeffrey M. Samuels & Linda B. Samuels, Lincoln and the Patent System: Inventor, Lawyer,
Orator, President, 3 ALB. GOVT L. REV. 645, 668-89 (2010).

15Douglas C. Limbach & David C. Cohen, PTO's Proposed Rule Changes Halted (for Now),
MED. DEVICE & DIAGNOSTIC INDUS. (Apr. 1, 2008), http://www.mddionline.com/article/ptosproposed-rule-changes-halted-now.
1635 U.S.C. § 103(a) (2006).
1 See, e.g., Stanle~y S. Green, The 'Flasht of Genius' Standard of Patentable Invention, 13
FORDHA1V L. REV. 84, 86-87 (1944).
1

s Diamond, 447 U.S. at, 316-17.

19

20

Id. at 319-21.

Id. at 309.

21 U.S. Patent No. 4,736,866 (filed June 22, 1984).
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The Court further advanced the Jeffersonian principle of liberal encouragement
of ingenuity in its decision in State Street Bank v. Signature Financial Group.22 This
ruling confirmed patent protection for a wide array of newly spawned financial and
internet businesses. 23 The most recent pronouncements of the Supreme Court in
Bilski v. KappoS24 regarding business and computer related patents addressed the
limitations of claiming such inventions. 25

C. The United States Abandoned its Longstanding "First-to-Invent"System in 2011
The USPTO has been the central point for combat between conflicting patent
claimants for several centuries. These interferences have included famous battles
over the rights to the telephone between Elisha Gray and Alexander Graham Bell,
where Bell was eventually awarded U.S. Patent No. 174,465.26 Other notable
interferences include McCreary v. Zworykin,27 for basic rights in early television
technology, and Consolidated Elec. Light Co. v. McKeesport Light Co. 28 over patents
pertaining to incandescent light bulbs. 29 In more recent times, protracted fighting
over the so called Ziegler catalysts occupied the USPTO and the Federal Courts on
appeal to adjudicate the legal right to produce large volumes of high quality
polypropylene. 30 The recent U.S. patent reform relegates such interferences and the
accompanying case law to the annals of history.
On September 16, 2011, President Barack Obama signed into law the latest U.S.
patent law reform , known as the Leahy-Smith, or America Invents Act ("AIA"). 31
The primary change to existing U.S. law enacted in AIA is the conversion from
"first-to-invent" to "first-to-file" inventorship criteria. 32 A number of the other
changes to the law flow from that major change, and these amendments are
discussed below.

Although Congress enacted meaningful changes in the patent law reform of
199533 and 1999,34 as discussed below, Congress had struggled for years whether to
22State Street Bank & Trust Co. v. Signature Fin. Grp., 149 F.3d 1368, 1372 (Fed. Cir. 1998).
23 Id. at 1373.
24Bilski v. Kappos, 130 S.Ct. 3218 (2010).
25 Id. at 3228-29.
26Mark A. Lemley, The Myth of the Sole Inventor, 110 MICH. L. REV. 709, 721 n.65 (2012).
27McCreary v. Zworykin, 19 C.C.P.A. 990, 993 (C.C.P.A. 1932).
The motion to dissolve by McCreary is practically a repetition of a motion to
dissolve as to Zworykin in interference No. 55448, Farnsworth v. Reynolds v. Case
v. Sabbah v. McCreary v. Zworykin. For reasons stated in the decision of the law
examiner in that interference the motion by McCreary is denied.
Id.

28Consol. Elec. Light Co. v. McKeesport Light Co., 159 U.S. 465 (1895).
29See J. Benjamin Bai, Enablement Issues Concerning Aggressively Broad Generic Claims, 7
Nw. J. TECH. & INTELL. PROP. 1, 2-3 (2008).
30See, e.g., U.S. Steel Corp. v. Phillips Petroleum Co., 865 F.2d 1247, 1249-50 (Fed. Cir. 1989).
31 Leahy-Smith America Invents Act, Pub. L. No. 112-29, 125 Stat. 284 (2011) [hereinafter
AIA].
32 Id. § 3.
33 Uruguay Round Agreements Act, Pub. L. 103-465, 108 Stat. 4809, 4973 (1994).
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change "first-to-invent" to "first-to-file" due to a variety of competing interests. In
2011 the clarion cry in Congress became "job creation" and resistance to reform,
including first-to-file, melted under that banner. 35
Historically, the current patent reform had been championed under a different
banner, i.e., harmonization.
The Intellectual Property Owners Association, an
organization that speaks for most of the major Fortune 500 patent chiefs, had long
argued for reform that would bring the U.S. patent system into harmony with the
patent systems of the rest of the world. 36 Prior to the enactment of AIA, all the other
countries of the world employed a system based on the first-to-file, while the U.S.
was the only country with a first-to-invent system.3 7 A first-to-invent system
requires adjudication of conflicting patent rights in "interference" proceedings within
the USPTO. 38 Interferences, rightly or wrongly, are labeled as costly, complex,
arcane and a few other labels not fit for publication.39
Critics of this "jobs" rationale for AIA point out that the number of interferences
is small and the overall impact of the change in the law will be muted with respect to
job creation; and that what will be lost is the fairness of awarding an invention to the
rightful first inventor. 40 Yet the proponents of AIA and the first-to-file system have
prevailed after more than half a century of debate, lobbying and counter-lobbying.
As was pointed out at the 2011 winter meeting of the Association of Corporate Patent
Counsel, the die-hard advocates of first-to-invent have retired, passed away or
dropped their opposition to first-to-file. 41
The chief patent counsel of large
corporations, responsible for larger quantities of filing, favors first-to-file as it results
in faster and more certain determination of patent rights. 42
Another point of Congressional spin on enactment of AIA is that the new law
represents the first major change in U.S. IP law in sixty years, and that the previous
law was stuck in the past. Such spin ignores the Inventors Protection Act of 199943

34 Intellectual Property and Communications Omnibus Reform Act of 1999, Pub. L. No. 106113, 113 Stat. 1051 [hereinafter Patent Reform Act of 1999].
35See Lynn Tyler, Patent Reform: Much Ado About Nothing or Will 2011 be the Year?, INSIDE
INDIANA Bus., http://www.insideindianabusiness.com/contributors.asp?id= 1904#middle (last visited
Apr. 16, 2012).
36 U.S.
Patent Reform Primer, INTELL. PROP. OWNERS ASSoC. (Oct. 20, 2009),
http://www.ipo.org/AM/Template.cfm?Section=IPODailyNews_&Template=/CM/HTMLDisplay.cfm
&ContentlD=24305#6.
37 See, e.g., Lisa C. Elsevier, Schendel v. Curtis: DNA Standards Misapplied to Fusion Protein
Patents, 3 J. INTELL. PROP. L. 353, 354 (1997).
38Airport Surface Tech., L.L.C. v. FieldTurf, Inc., 268 F. Supp. 2d 999, 1002 (N.D. Ill. 2003).
39 See Eli Lilly & Co. v. Bd. of Regents of Univ. of Wash., 334 F.3d 1264, 1274 (Fed. Cir. 2003)
(Lourie, J., dissenting).
40See United States Now a 'First to File' Jurisdiction, MANDOUR & ASSOC. (Sept. 27, 2011),
http://www.losangelespatentattorney.pro/20 11/09/united-states-now-a-first-to-file-jurisdiction.html.
41See generally Ass'n of Corp. Patent Counsel, Professional Program in San Diego (Jan. 16-18,
2012) (exhibiting a variety of opinions agreeing that the voice of first-to-invent advocates has died
down).
42See Cyndia Zwahlen, Patent Measure Causing Concern Among Independent Inventors, L.A.
TIMES (July 11, 2011), http://articles.1atimes.com/201 1/jul/i11/business/1a-fi-smallbiz-patents201107 11.
43 Patent Reform Act of 1999, supra note 34.
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and other changes in the Patent Reform Act of 1995.44 In these prior patent reform
acts, changes included ending the longstanding practice of keeping U.S. patent
applications secret and allowing publication of most applications eighteen months
after first filing. 45 In addition, the 1995 reforms relaxed interference laws to level the
playing field so that proof of first invention made abroad is on the same footing as
evidence generated in the United States. 46 At the same time, the duration of a U.S.
patent was changed from seventeen years from the time the patent was granted to
the time between patent issue and twenty years from the filing date. 47 The 1999 Act
set up inter partes reexamination, thereby permitting more effective challenges to
potentially invalid patents that block rights in the way of commercialization and job
creation. 48
While the change to first-to-file was strongly opposed by the small inventor
organizations and was omitted from the 1999 amendments, 49 arguably the Inventors
Protection Act of 1999 was as significant as the harmonization in AIA. The major
points of the 1995 and 1999 changes discussed above remain in force in AIA.

D. Echoes of Chinese Patent Philosophy in A1A
The U.S., unlike centrally-directed China, does not promulgate a unitary set of
strategic goals for patenting or development of technologies. Rather, goals are set by
many different government agencies and private entities that are free to plan for the
future as they see fit.
However, at least one AIA provision might be interpreted as a Chinese style
directive.
In section 25, the USPTO is required to establish regulations for
prioritizing applications for products and processes that are important for national
competitiveness without recovering the excess cost of such examinations. 50 That is to
say the USPTO is being directed to identify and speed up granting of patents on "hot"
technologies that should make the U.S. more competitive in world markets. While
numerical goals are not being set, as in China, technological targets or goals are
being established by the U.S. government in the process. The USPTO is directed to
complete this review by September 2012, although it is not clear what happens if this
timetable is not met. 51 Progress on this task will likely be watched closely by China
and other countries hoping to gain intelligence on U.S. government priorities for
sponsoring innovation.
44 Patent Reexamination Reform Act of 1995, H.R. 1732 104th Cong. (1995) (codified as
amended at 35 U.S.C. § 122).
45 35 U.S.C. § 122 (2006).
46Uruguay Round Agreements Act, supra note 33, § 531.
47 35 U.S.C. § 154(c)(1).
48James W. Beard, A Better Carrot Incentivizing Patent Reexamination, 1 HASTINGS SCI. &
TECH. L.J. 169, 175 (2009).
49 See Edward Wyatt, Senate Passes Bill to Change Patent System and Pricing, N.Y. TIMES,
Mar. 8, 2011, at B9.
50 AIA, § 25 (to be codified at 35 U.S.C. § 2(b)(2)).
51U.S. PAT. & TRADEMARK OFF., MONTHLY REPORT ON AIA IMPLEMENTATION (Nov. 16, 2011),
available at http://www.uspto.gov/aia implementation/201 1-nov-aia report.pdf.
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II. THE SINo-AMERICAN PATENT LAW DIVIDE
In preparing the analysis in this section, the authors have relied on an official
translation of the Chinese Laws and Regulations and in part on Peksung IP partner,
Stephen Yang's excellent analysis in February 2010 titled, "China Patent Prosecution
Practice & Latest Development." 52

A. Chinese Utility Model Patents can Lead to Swift Justice.
China has one type of patent protection that has no parallel in the U.S. This is
the utility model patent, which provides short term protection (ten years) under a
simplified examination process. 53 SIPO examines the utility model only for formal
requirements but does not search or apply prior art. 54 This results in the grant of
such a patent in less than one year.55
Utility models are popular in China, and under the latest amendments in 2009
they may be filed concurrently with "invention" patents under certain
circumstances. 56 Only one patent may be granted, however, and the applicant must
elect to withdraw one or the other to prevent double patenting.5 7 The popularity of
the utility model stems from the quick patent grant that may be asserted
immediately in court following its grant by SIPO. Since it is not examined for prior
art in SIPO, generally the Chinese trial court requires the plaintiff to file a patent
search and analysis to demonstrate the validity of the claims being asserted in the
infringement action.5 8 Chinese Patent Law ("C.P.L.") article 61 states that a patent
assessment report may be required. 59 In addition, the plaintiff in an infringement
suit must show how each and every element of the defendant's product is captured
within at least one claim of plaintiffs utility model patent. 60 If the patent holder
prevails, he may swiftly abate the infringement-often stopping infringing conduct,
obtaining damages, and even receiving a public apology for the misconduct. 61
One drawback of a utility model patent is that its life is limited to ten years from
filing instead of twenty years for an "invention" patent. 62 Depending on the life of the
patent, this may not be a significant problem, e.g., in semiconductors and electronics
52See Stephen Yang, Partner, Peksung Intellectual Property Ltd., Presentation at the
Association of Patent Law Firms February 2010 Meeting, China Patent Prosecution Practice
& Latest Development: What U.S. Attorneys Should Know and Do (Feb. 2010).
53Chinese Patent Law, supra note 4, art. 42.
54 SIPO Guidelines, supra note 7, at R.44.1.
5 Uma Suthersanen, Utility Models and Innovation in Developing Countries 20 (Int'l Ctr. for
Trade
and
Sustainable
Dev.,
Working
Paper
No.
13,
2006),
available at
http://www.unctad.org/en/docs/iteipc20066_en.pdf.
56 Chinese Patent Law, supra note 4, art. 9.
58 Id.

art. 61.

6 Id.
60 J. Benjamin Bai et al., What Multinational Companies Need to Know About Patent
Invalidation and Patent Litigation in China, 5 Nw. J. TECH. & INTELL. PROP. 449, 460-61 (2007).
61 Id. at 461-62.
62Chinese Patent Law, supra note 4, art. 42.
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where the life cycle for certain products is relatively short. Many chemicals and
pharmaceuticals, however, take a long time in development and count on extended
protection offered by an "invention" patent. Processes are not generally considered
proper subject matter for utility model patents. 63
Utility models or "small" patents are employed in other countries such as
Germany, a country which China emulated when drafting its patent laws. 64
Seasoned IP professionals such as Karl Jorda, retired professor of IP law at Franklin
Pierce Law School have suggested amending U.S. patent law to include utility model
patents. 65 However, this movement did not gain sufficient traction to be included in
AIA.
The value of Chinese utility model patent is illustrated by Schneider Elecs.66 In
that case, Schneider was sued for infringement of a utility model patent issued to the
Chint Group of China. 67 Schneider was ordered by the Intermediate Court in
Wenzhou to pay money damages amounting to over $44 million. 68 This is the largest
damage award in Chinese history and was hotly contested by Schneider. 69 On
appeal, the parties settled the case. In the past, only very modest damages were
awarded by Chinese courts. 70 Whether or not this award would have been ultimately
confirmed, it demonstrates recognition by the Chinese courts that meaningful
damage awards are necessary to establish respect for the rights of patent owners,
including those based on utility model patents.

B. Patent Application Filing and Prosecution in China and the United States

1. Many Similarities Between the Practices
The overall number of similarities-in the filing processes, prosecuting by
responding to patent office actions, granting, and maintaining of applications and
granted patents-are impressive.
However, there are important differences in
details and, in some cases, in subtle culturally-based philosophical differences that
can lead to a different result given the same set of facts. However, global businesses
that file applications in the U.S. often file counterpart applications in China, and
recently Chinese enterprises are filing more of their Chinese invented applications
63 Suthersanen, supra note 55, at 1-2.
641d.

at 16.

65Karl F. Jorda, Utility Models: The Panacea for Our Broken Patent System, GERMESHAUSEN
CENTER NEWSL. (Franklin Pierce Law Center) Winter/Spring 2007, at 12.
66Chint v. Schneider, Wenzhou Intermediate People's Court, Wenzhou, Zhejiang Province, P.

R. China (Sept. 26, 2007).
67Industry Report, China: Intellectual Property Infringement, Indigenous Innovation Policies,
and Frameworks for Measuring the Effects on the U.S. Economy, Inv. No. 332-514, USITC Pub. 4199
at 54 (Nov. 2008) [hereinafter USITC Pub. 4199].
68Id.; IP AND ANTITRUST: AN ANALYSIS OF ANTITRUST PRINCIPLES APPLIED TO INTELLECTUAL
PROPERTY LAW § 47.2 n.75 (Wolters Kluwer 2011).
69 USITC Pub. 4199, supra note 67, at 54-55.
70 Id.
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abroad. 71 Chinese attorneys in many larger Chinese firms are fluent in English. 72
While few U.S. patent attorneys know the Chinese language, 7 3 attorneys of Chinese
origin in many firms who are fluent in Mandarin are on hand to handle the nuances.
While the Chinese and U.S. governments at the top levels at times exhibit hostile
behavior toward each other, the working relationships among the respective IP and
legal communities on both sides seems to be pleasant and productive.

2. Differences in Patent Eligible Subject Matter
Turning now to some areas where differences exist, article 25 of the C.P.L.
specifies subject matter that cannot be patented in China. 74 Included are several
categories that would appear to be patentable under section 101 of the U.S. Patent
Act ("section 101") and U.S. case law. These prohibited categories include: methods
for diagnosis or treatment of diseases; animal and plant varieties; and substances
obtained by nuclear transformation. 75
Under U.S. law, unlike in China, processes for diagnosis or treatment of diseases
are routinely patented as methods or processes authorized by section 101.76 Chinese
practitioners advise that diagnosis or treatment of diseases may be patented by using
Swiss-type claims.77 Animal varieties are patentable such as the Harvard mouse
provided they are the product of genetic manipulation and hybrid plant varieties and
patentable by virtue of section 161 of the U.S. Patent Act, where the patenting of
hybrid plants is specifically authorized.7 8 Finally, any new and useful product is
patent eligible under section 101 whether by nuclear transformation or otherwise. 79

71See WIPO ECON. & STATSISTICS DIV., WORLD INTELLECTUAL PROPERTY INDICATORS 6 (Dec.
2011), available at http://www.wipo.int/ipstats/en/statistics/patents/ (noting the growth in Chinese
PCT filings).
72 See Anne M. Wall, Intellectual Property Protection in China: Enforcing Trademark Rights,
17 MARQ. SPORTS L. REV. 341, 365 (2006).
73See Jonathan Adams, English for Everyone, DAILY BEAST (Aug. 15, 2007),
http://www.thedailybeast.com/newsweek/2007/08/15/english-for-everyone.html
(comparing
the
number of non-native speakers studying Mandarin with those studying English); Chinese Patent
Attorneys
and
Agents,
ABACUS
CHINESE
TRANSLATION,
http://www.certifiedchinesetranslation.com/Chinese-patent-attorneys.html
(last visited Apr. 16,

2012).
4 Chinese Patent Law, supra note 4, art. 25.

TSId.

76See Ass'n for Molecular Pathology v. U.S.P.T.O., 653 F.3d 1329, 1357-58 (Fed. Cir. 2011);
U.S. Patent No. 7,741,025 (filed Sept. 10, 2007); U.S. Patent No. 6,545,014 (filed June 15, 2001).
7See Liantao Li & Tina H. Tai, Feares of Swiss-Type Claims, MANAGING INTELL. PROP.
(Apr.
1,
2009),
http://www.managingip.com/Article/2175956/Search/Features-of-Swiss-typeclaims.html?Home true&Keywords=FEATURES+OF+SWISS-TYPE+CLAIMS&Brand=Site&tabSel
ected= True.
7835 U.S.C. § 161 (2006).
79 See id. §101.
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3. Chinese Applications are Not Automatically Examined by SIPO
When a patent application is filed with the USPTO it is placed in line in the
back of earlier-filed applications; but then it is taken up for substantive examination
against the prior art as soon as its turn arises.8 0 Chinese "invention" applications are
not automatically examined according to article 35 of the C.P.L. 81 At any time within
the first three years of pendency before SIPO, an applicant may request examination.
If no request is made within the three year period, the application is deemed
withdrawn unless justification for failure to make a timely request can be
demonstrated. 82

4. Applicants in the United States Must Submit Known PriorArt References but the
Chinese Practice is Less Clear
Applicants in China are instructed to submit known prior art references in
article 36 of the C.P.L., however, no punishment is provided for failure to do so. 83 In
respect to prior art cited on applications for foreign counterparts, the applicant in
China must submit such prior art if requested by the examiner. 84 Failure to submit
may result in withdrawal of the application unless a good reason is demonstrated for
not doing so. 85 Applicants in China are not under an obligation to search for prior
art. 86 Such a search also is not required for the USPTO, however, U.S. applicants are
duty bound to submit known reference materials under their duty of candor.87
Failure to supply all known reference materials can result in a defense to
enforcement of any granted patents based on the charge of inequitable conduct or
fraud on the patent office. 88 In addition, the patent attorneys involved may be
sanctioned or even barred from practice by the USPTO. 89

5. Post Application Data is Not Accepted in China
One very different aspect of practice in SIPO versus the USPTO is the treatment
of data collected after the filing of an application. Both article 26 of the C.P.L. and
section 112 of the current U.S. Patent Act require a clear and complete description of
the invention so as to enable a skilled person to carry it out as well as claims that

80 U.S. PAT. & TRADEMARK OFFICE, U.S. DEP'T OF COMMERCE, MANUAL OF PATENT EXAMINING
PROCEDURE § 708 (8th ed. 8th rev. 8, July 2010) [hereinafter MPEP].
81 Chinese Patent Law, supra note 4, art. 35.

Id.
Id. art. 36.
84 Id.
85 Id.
86 Id. art. 26.
87 37 C.F.R. § 1.56(a) (2010).
88 Larson Mfg. Co. of S.D. v. Aluminart Prods. Ltd., 559 F.3d 1317, 1326 (Fed. Cir. 2009).
89 See Weiffenbach v. Logan, 27 U.S.P.Q.2d (BNA) 1870, 1 (Dec. Comr Pat. 1993).
82
83
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clearly point out the invention sought to be protected. 90 However, for example, where
a claim is rejected on the basis of obviousness or as not inventive it is often desired to
demonstrate by comparative data that even though the two products are quite
similar, the performance of the claimed product is different and surprisingly better
than the prior art. If the data sought to be employed is not already in the patent
application having been generated after filing, SIPO usually does not permit the use
of such data to prove "inventiveness".91 On the U.S. side, 37 C.F.R. 132 authorizes
the submission of factual information, data and statements by experts commenting
on patentability of the claimed subject matter. 92 The USPTO and the Courts have
routinely accepted post application performance data for chemical and drug
compositions and for other products. 93 The lack of acceptance of post-filing generated
data is a great concern for pharmaceuticals where the practice is to file early on a
promising composition and then generate supplementary and comparative data later
on. This is a significant bone of contention with the Chinese patent authorities.
Another significant difference arises out of the Chinese requirement for legalization
and further back up proof of the authenticity of documents as evidence in court or
SIPO proceedings. 94

6. "Best Mode"
Historically, the U.S. patent statutes have required that the inventor include in
the application the best mode of an invention as contemplated at the time of the
invention. 95 Failure to include the best mode is a defense to validity that has been
often raised in infringement suits with infrequent success. 96
No best mode
requirement is included in the Chinese law which only requires that the description
is clear enough to allow a skilled person to carry out the invention. 97 AIA expressly
eliminates "best mode" as a defense to infringement but does not remove the mention
of best mode in the statute. 98 Thus, it is not clear whether an inventor is required to
include the best mode; and the practice that is to be followed is equally unclear. Over
the years, best mode has been a concern for inventors trying to decide whether to file

90

Chinese Patent Law, supra note 4, art. 26; 35 U.S.C. § 112 (2006).

91See Antoinette Koski, IP.- Are We There Yet? How to Meet Chinese Patent Law Data
Disclosure
Requirements,
INSIDE
COUNSEL
(Jan.
4,
2011),

http://www.insidecounsel.com/2011/01/04/ip-are-we-there-yet-how-to-meet-chinese-patent-law-datadisclosure-requirements.
9237 C.F.R. § 1.132 (2010).
93 See, e.g., Yeda Res. & Dev. Co. v. Imclone Sys. Inc., 443 F. Supp. 2d 570, 627 (S.D.N.Y. 2006).
94 Bai, supra note 60, at 454.
95 See 35 U.S.C. § 112.
96See Bayer AG v. Schein Pharms. Inc., 301 F.3d 1306, 1321, 1323 (Fed. Cir'. 2002) (explaining
that the preference the defendant claimed should be included in the application did not materially
affect the carrying out of the invention and, therefore, did not need to be disclosed for compliance
with the best mode requirement).
97 Chinese Patent Law, supra note 4, art. 26.
98 35 U.S.C. §§ 112, 282.
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for patent protection where the best mode must be disclosed or keep the invention
secret and risk copying.99

a. ContinuationApplications are Permitted at the USPTO but Not SIPO

Another significant difference relates to methods of keeping applications
pending in order to have an opportunity to present new arguments to the patent
office regarding patentability. In the U.S., after a final rejection by an examiner, an
applicant may continue the dialogue with the examiner by filing a request for
continued examination, or a continuation application. 100 This can keep a U.S.
application alive for many years.
However, Chinese law does not yet permit filing applications to keep prosecution
pending except in the limited circumstances where the examiner has required
division of the claimed subject matter into separate applications. 101 Hence, upon
final rejection of a Chinese application, an applicant's only option is an appeal to the
Patent Reexamination Board ("P.R.B."), 102 which is akin to the USPTO Board of
Patent Appeals and Interferences ("B.P.A.I."). 103 Chinese law only permits the filing
of divisional applications where the examiner requires an election of inventions in
the original application. 1 04 Thus, one way to leave open the possibility of multiple
applications in China is to file claims in the initial application with a disparate scope
of subject matter that will likely draw a restriction requirement.

C. The Patent Appeals Process in China and the United States
Similar to the process in the United States, Chinese applicants on final rejection
may appeal to the aforementioned P.R.B. for review of patentability of their claims.
U.S. applicants may appeal to the B.P.A.I. which will become the Patent Trial and
Appeal Board ("P.T.A.B.") under AIA. 105
Applicants dissatisfied with the decision of the P.R.B. in China may bring a
lawsuit in the Beijing No. 1 Intermediate People's Court. 1 06 U.S. applicants may
99 See, e.g., Glaxo Inc. v. Novopharm Ltd., 52 F.3d 1043, 1046 (Fed. Cir. 1995) (discussing a
debate between the patent attorney and the inventor on whether to disclose the azeotropic
granulation process when the inventor wanted to keep it secret, but felt it was the best way to make
Form 2 salt).
10037 C.F.R. § 1.114 (2010); 35 U.S.C. § 302.
101Implementing Regulations, supra note 5, at R.42.
102Chinese Patent Law, supra note 4, art. 41.
103Haitao Sun, Post-Grant Patent Invalidation in China and in the United States, Europe, and
Japan: A Comparative Study, 15 FORDHAM INTELL. PROP. MEDIA & ENT. L.J. 273, 288-89; see also
35 U.S.C. § 6.
104 Implementing Regulations, supra note 5, at R.42.
105AIA, § 3(j) (to be codified at 35 U.S.C §§ 134, 145, 146, 154, 305) (noting that each provision
will be amended by striking "Board of Patent Appeals and Interferences" each place it appears and
inserting "Patent Trial and Appeal Board").
106Chinese Patent Law, supra note 4, art. 41.
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appeal adverse decisions on patentability to the Court of Appeals for the Federal
Circuit or to the Federal District Court in the District of Colombia. 107 Appeals to the
Federal Circuit are based on the USPTO record, while appeals to the District Court
are brought when additional witnesses or evidence are needed to supplement the
record.108

D. Reexamination for Invalidity
The Chinese P.R.B. also handles petitions for reexamination of granted patents
where an adverse party asserts invalidity of a granted patent. 109 The grounds for
reexamination in China include, but are not limited to, prior art and sufficiency of
disclosure as set forth in the Chinese Implementing Regulations. 110 Fraud and
inequitable conduct are not permitted as bases for challenging a patent in China.
The USPTO also has reexamination processes where the patentee may try to
reinforce validity, or third parties may challenge the validity, of a granted patent.
Similar to China the U.S. reexamination can be ex parte1 1 or inter partes.112
However, the Chinese reexaminations are decided by the P.R.B. while one or more
examiners decide U.S. reexaminations. A reexamination decision adverse to either
the patentee or third party requester is reviewable by the B.P.A.I.
The U.S. process will change under AIA, however, to permit inter partes
reexaminations to be conducted directly before the reincarnated P.T.A.B. 113 Chinese
reexamination can be brought any time after grant, whereas in the new U.S. system
inter partes review ("I.P.R.") 114 cannot be filed until conclusion of a new U.S.
procedure called post grant review ("P.G.R."). 115
Under the changes enacted by AIA, the newly constituted P.T.A.B. will handle a
wide array of appeals including ex parte appeals of rejected patent claims,
reexamination for invalidity, and opposition appeals. 1 1 6 That consolidation in the
USPTO is similar to, but goes further than, the Chinese patents appeals system.
Changes in AIA will complicate the treatment of invalidity where, in new P.G.R.
proceedings or in I.P.R., issues of validity decided by USPTO give rise to the defense
of estoppel in a later court action thereby preventing re-litigation of the same issues
of invalidity.117

37 C.F.R. § 1.983 (2010).
35 U.S.C. § 145.
109 Chinese Patent Law, supra note 4, art. 45-46.
110Id.; Implementing Regulations, supra note 5, R.65.
11135 U.S.C. § 302.
112Id. § 311.
113AIA, § 6(a) (to be codified at 35 U.S.C. § 3 16(c)).
114 Id
115See infra Part III.
116
AIA, § 7(a)(1) (to be codified at 35 U.S.C. § 6(b))
117Hung H. Bui, An Overview of Patent Reform Act of 2011: Navigating the Leahy-Smith
America Invents Act Including Effective Dates for Patent Reform, 93 J. PAT. & TRADEMARK OFF.
SOC'Y 441, 464 (2011).
107
108
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E. The Chinese System has No Equivalent to U.S. Reissue Proceedings to Correct Major
Patent Defects.
China has no proceedings to correct granted patents comparable to U.S. reissue
proceedings. 118 Only typographical errors may be corrected at the discretion of
SIPO.119 By contrast, in the United States, past and current law permits correction
of granted patents by permitting changes to claims in reissue, reexamination, and,
soon, P.G.R. proceedings.

F. Beware of the Chinese P.R.B.'s Ex Officio Powers.
Under Chinese practice, once a reexamination proceeding has been initiated,
whether by a party adverse to the patentee or by the inventors who may be seeking
to enhance the validity of their own patent, the P.R.B. may initiate examination ex
officio, or on its own. 120 Such examination or appeal may go beyond the requested
scope, ground, and/or evidence produced by the parties and may be continued by the
P.R.B. even if the request is withdrawn or the case is settled. 121 Chinese attorneys
recommend withdrawing before substantive examination is started if one must
withdraw and, where a less aggressive approach seems reasonable, that the patent
holder consider settlement prior to oral hearing. 122

G. Litigation in China.
One major difference between the patent litigation systems of China and the
United States is that U.S. courts permit the adjudication of both invalidity and
infringement in a single judicial setting. 1 23 In China, invalidity is decided by
SIPO;124 infringement is decided in the courts.1 25 Thus, if a person is sued in China
for infringement, the court will decide that issue. The accused party can take the
issue of invalidity to SIPO.126 However, article 62 of the C.P.L. provides that in a
dispute over patent infringement, "if the alleged infringer has evidence proving its or
his technology or design belongs to the prior art or is a prior design, it will not
constitute patent infringement." 127 Thus if an accused infringer can show he is
copying a prior product, the infringement court may rule in his favor. On the other

118See, e.g., 35 U.S.C. § 251 (2006).
119SIPO Guidelines, supra note 7, at 590.
120 Id. at 426.
121

Id.

122 See id.

123 See, e.g., Uniloc U.S.A., Inc. v. Microsoft Corp., 632 F.3d 1292, 1323 (Fed. Cir. 2011)
(addressing both invalidity and infringement).
124 Chinese Patent Law, supra note 4, art. 45.
125 Id. art 61
126 See Sun, supra note 103, at 292.
127 Chinese Patent Law, supra note 4, art. 62.
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hand, where, for example, an analysis for prior art is needed to prove lack of
inventiveness it is likely that would have to be decided by the experts in SIPO.
Initiation of a lawsuit for infringement is somewhat different in China than in
the United States. Article 60 of the C.P.L. states that parties "shall" settle disputes
through negotiation. 1 28 If negotiations fail, the patentee can bring a lawsuit in the
People's court or request the local patent administrative authority for settlement. 129
The administrative authority has the power to order the infringer to stop
infringement and request mediation for payment
of compensation for
infringement.130 Parties dissatisfied with rulings of the administrative authority
may bring a lawsuit in the People's court. 131 In reality, most patent infringement
actions are brought in court and not in the patent administrative authority. 132
In regard to the standard of proof required to prevail, in the U.S. courts, the
patent holder must prove infringement by a preponderance of the evidence. 1 33 Article
61 of the C.P.L., by contrast, requires the accused infringer to provide proof of the
difference between his process used for making a product and the patented
process. 134 U.S. patents enjoy a presumption of validity in the courts which means
that an accused infringer must overcome the presumption by clear and convincing
evidence. 135 In reexamination of patents in the U.S., the standard of invalidity is a
simple preponderance of the evidence. 136
The procedures for gathering information to litigate are quite different in China
than in the United States. Unlike in the U.S., where discovery is a dominant part of
litigation, there is no U.S.-style discovery in China. 1 37 However, if there is an
evidentiary basis to suspect infringement during an investigation by the
administrative authority, the authority may query the parties so as to find relevant
information to the suspected violation and may conduct an on-site inspection over the
site of the party suspected of having committed the violation. 1 38 Further, the
authority has the power to copy relevant contracts and invoices, check out suspected
products, and confiscate suspected counterfeit products. 1 39 Also, once pertinent
information is identified, a Chinese court may enter an order requiring the custodian

128

Id. art. 60.

129 Id.
130

Id

131 Id.
132 Compare ST. INTELL. PROP. OFF., PATENT STATISTICS ANNUAL REPORT 199 (2009), available
at http://www.sipo.gov.cn/tjxx/2009.pdf (noting that in 2009, the patent administrative authority
entertained 15,771 patent infringement issues), with Shengping Yang, Patent Enforcement in China,
4 LANDSLIDE 48, 48 (2011) (explaining that in 2010, "the local people's courts received ... a total of
42,931 civil intellectual property ... cases.").
133CrOSS Med. Prods., Inc. v. Medtronic Sofamor Danek, Inc., 424 F.3d 1293, 1310 (Fed. Cir.
2005).
134Chinese Patent Law, supra note 4, art. 61.
13535 U SC § 282 (2006); Microsoft Corp. v. i4i Ltd. P'ship, 131 S.Ct. 2238, 2242 (2011)
(affirming rule that proof of invalidity requires clear and convincing evidence).
136In re Swanson, 540 F.3d 1368, 1377 (Fed. Cir. 2008).
137See Louis S. Sorell, A ComparativeAnalysis of Selected Aspects of Patent Law in China and
the United States, 11 PAC. RIM L. & POL'Y J. 319, 332 (2002).
138Chinese Patent Law, supra note 4, art. 64.
139 Id.
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to preserve that information. 140 Less draconian, more informal measures to gather
information, such as use of private investigators, are widely used in Chinese
litigation. 141 Because of the lack of formal discovery, it is often necessary to employ a
private investigator to obtain sufficient information to start an administrative action
or lawsuit. 1 42
Western observers are often surprised to learn of the rules for acceptance of
proof in Chinese proceedings.
Notarization is required for acceptance of most
documents. 143 Beyond notarization, it may be required to obtain proof that the
notary is duly authorized. 144 These additional procedures are frustrating and often
cause delay for foreign litigants in China. There is a healthy distrust of evidence
offered on a partisan basis hence the additional requirements for documentary proof.
Additionally, the Supreme People's Court has required that testimony be crossexamined to be accepted as a basis for holding infringement. 1 45 By contrast, in U.S.
litigation, statements made in court and under oath are accepted as evidence even if
the adverse party decides not to cross-examine the witness. 1 46
In the U.S., litigation may be commenced by filing and serving a complaint in
the appropriate Federal District Court subject to venue considerations. A complaint
may be filed alleging infringement based on information and belief even if a diligent
effort has not yet uncovered substantial proof of infringement. 147 The U.S. statutes
offer ample opportunity for the plaintiff patent holder to require the accused
infringer to surrender all relevant information. 1 48 The plaintiff can require the
defendant to turn over copies of a wide range of documents pertinent to the alleged
infringement; and then can depose witnesses including managers, financial, sales
and technical employees of the defendant. 149 Products may be inspected and

140 Chinese Patent Law, supra note 4, art. 67.
141 See generally Robert Bejesky, Investing in the Dragon: Managing the Patent Versus Trade
Secret Protection Decision for the Multinational Corporationin China, 11 TULSA J. COMP. & INT'L L.
437, 488 (2004) ("As soon as an IP right infringement is suspected, a private investigator should be
hired to trace the source of the infringement to decrease the extent of loss prior to an enforcement
action.").
142 Id
143 Civil Procedure Law of the People's Republic of China (promulgated by Standing Comm'n
Nat'l People's Cong., effective Apr. 9, 1991) art. 67 ("The people's court shall take the legal acts, legal
facts and documents notarized according to legal procedures as basis for ascertaining facts, except
when there is contrary evidence sufficient to invalidate the notarial certification.").
144 See id.
145 CCPIT PAT. & TRADEMARK LAW OFF., SELECTED INTELLECTUAL PROPERTY CASES IN CHINA

18-20 (Ma Hao, ed., 2009) [hereinafter SELECTED IP CASES] (discussing the opinion of the Supreme
People's Court of China opinion in Zhenshong v. Jiansong).
146 See, e.g., FED. R. EVID. 601.
147 Richard A. Kamprath, Patent Pleading Standards After Iqbal: Applying Infringement
Contentions as a Guide, 13 SMU SCI. & TECH. L. REV. 301, 309-10 (2010) (stating that "the plaintiff
should plead facts showing or supporting an inference of misconduct by the defendant.").
148 See, e.g., FED. R. CIV. P. 34(a).
149 See id. (discussing the rules for producing documents); id. 30(c) (discussing the rules for
depositions by oral examination).
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analytical information retrieved. 15 0
There are substantial penalties for the
destruction of evidence including fines and even an adverse judgment. 15 1
The statute of limitations under the C.P.L. is quite short, being two years
counted from date the patentee or plaintiff knew or should have known of the
infringement. 152 By contrast the statute of limitations in the United States is six
years. However, the doctrine of laches might apply earlier than the onset of the
statute of limitation, severely limiting the compensation or damages that the
defendant could recover. 153
Damages or compensation for infringement are wildly different in U.S. litigation
from Chinese patent suits. U.S. awards have reached into the billions of dollars and
recoveries in the millions of dollars are quite common. 1 54 In the 2009 infringement
suit, Centocor Ortho Biotech v. Abbott Labs., 15 5 the plaintiff was awarded $1.67
billion in damages. Article 63 of the C.P.L. speaks of civil and criminal liabilities and
sets forth a fine of 200,000 Yuan (about $31,700 USD). 156 The award of $44 million
in Schneider Elecs. was quite unusual as very low damage awards are commonplace
in China at the present time. Damage awards are likely to increase as the patent
law matures in the Chinese courts and the need for stronger enforcement is more
fully recognized.
Western observers often raise major concerns about the fairness of Chinese
courts in deciding issues of social or political interest in China. Pfizer's Viagra
product and contested patent application is an example of a situation where the
Beijing High Court intervened to maintain the validity of Pfizer's patent and correct
a potentially embarrassing injustice. 1 57 The Court submerged the short term
interests of a large number of Chinese companies that stood ready to copy Pfizer's
patented product and satisfy the market against the interests of Pfizer to help
preserve China's reputation and compliance with international intellectual property
treaties.158

Id. 34(a)(1).
151 Id. 37(b).
150

152 Chinese Patent Law, supra note 4, art. 68.
153 A.C. Aukerman Co. v. R.L. Chaides Const. Co., 960 F.2d 1020, 1028 (Fed. Cir. 1992) ("The
Supreme Court has long recognized the defense of laches to a patent infringement action brought in
equity.").
154 See, e.g., Lucent Techs., Inc. v. Gateway, Inc., 580 F.3d 1301, 1308 (Fed. Cir. 2009)
(resulting in a $357,693,056.18 jury award); see generally Martha K. Gooding & William C.
Rooklidge, The Real Problem with Patent Infringement Damages, 91 J. PAT. & TRADEMARK OFF.
SOC'y 484, 486 (2009) (documenting several large jury awards).
155 Centocor Ortho Biotech v. Abbott Labs., 636 F.3d 1341, 1344 (Fed. Cir. 2011).
156 Chinese Patent Law, supra note 4, art. 63.
157 Geoff Dyer, Pfizer's Viagra Patent Upheld in China, FIN. TIMES (Dec. 28, 2006),
http://www.ft .com/cms/s/0/3008419c-96a3-11ldb-8bal-0000779e2340.html;
Newsletters Regarding
IPR,
CHINA
DAILY
(Nov.
5,
2007),
http://www.sipo.gov.cn/sipoEnglish2008/news/iprspecial/200904/t2009041 7_452899.html.
158 Tai Hong & Cheng Miao, What Can be Learned from the Case of Viagra Patent Invalidation,
2 CHINA PATS. & TRADEMARKS 52, 55 (2008); see also Timothy Roe, Pfizer Emerges Victorious in
China Viagra Patent Battle, SEEKING ALPHA (Nov. 5, 2007), http://seekingalpha.com/article/52698pfizer-emerges-victorious-in-china-viagra-patent-battle.
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Unlike in the U.S. where there is systematic reporting and abstracts of decisions
in lawsuits at all levels of the court systems, reports of Chinese cases are sporadic at
present. Except for certain Supreme Court "judicial interpretations" which are
binding on lower courts, the effect of prior case law as a binding precedent is not part
of the Chinese legal system. 159 CCPIT Patent and Trademark Office, one of the oldest
patent law firms in China, recently produced an English translation of some of the
leading cases, which is helpful in providing insight to foreigners into the rationale of
Chinese Courts. 160

H. Third Party Submission of References and Comments is Prevalent in China; U.S.
Applicants Are Wary of "Estoppel"
Another significant difference in practice between SIPO and the USPTO relates
to third party submission of references and observations. Under both AIA1 61 and
China's latest patent reform, 162 third parties can submit patents and other references
to the patent examiner following publication of the application in an effort to block
the granting of a patent.
In the U.S., interested third parties are quite reluctant to submit references
with or without comments for fear that the examiner will not see the references as
invalidating pending claims and simply list the reference as having been
considered. 163 That denigrates the value of such a reference in later invalidation
proceedings in the U.S. legal system, while no such prejudice exists in China. 1 64
Hence there is little to lose by submitting such a reference in China whereas caution
is advisable in the United States.
The written prosecution history, including
remarks of the applicant and the examiner, may be employed at each successive
stage in the USPTO and in court to detect inconsistencies and especially to find
potentially prejudicial remarks of the patent applicant to overcome a reference and
limit claimed subject matter. 165 China also has a guide on prosecution history that
applies to applicant's amendments and statements that limit claims. 1 66 Some
Chinese attorneys advise that the submission of references be made anonymously.

159See The China Law Center Co-Sponsors Workshop and Training on Judicial Precedent in
22,
2007),
Jiangsu
Province,
YALE
LAW
SCHOOL
(July
http://www.law.yale.edu/intellectuallife/5346.htm# ("China is a civil law system and thus does not
recognize judicial precedents as binding in later cases.").
160See generally SELECTED IP CASES, supra note 145.
161 AIA, § 6 (to be codified in scattered sections of 35 U.S.C.).
162 Implementing Regulations, supra note 5, at R.48.
163Mark D. Janis, Rethinking Reexamination: Toward A Viable Administrative Revocation
System for U.S. Patent Law, 11 HARV. J.L. & TECH. 1, 69 (1997) ("The existing reexamination
provisions severely restrict public participation in the reexamination process.").
164 Implementing Regulations, supra note 5, at R.67.
165Ormco Corp. v. Align Tech., Inc., 498 F.3d 1307, 1314 (Fed. Cir. 2007) ("[T]he prosecution
history can often inform the meaning of the claim language") (emphasis omitted).
166China Clarifies Principles and Rules of Patent Protection, CMS CAMERON MCKENNA (Apr.
8, 2010), http://www.1aw-now.com/aw-now/2010/chinapatentapril2010.htm?cmckreg true.
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L Unlike the United States, China Requires Inventor's Remuneration
Another feature of Chinese law that is distinctly different from American
practice is the requirement that employers set up policies for payment to inventors
for inventions that are related to their workplace responsibilities or so called service
inventions. 167 This is another aspect of German patent law adopted by China. 1 68
Under the 2008 reform act, an employer in China may establish any system that
fairly compensates the inventors for each invention or patent, but such a
requirement is quite burdensome and requires expensive bookkeeping in order to
assure compliance. 169
If an employer fails to adopt and adhere to its own policy, an inventor may
recover compensation based on China's state policy, which is very favorable to
inventors. 170 American and other global companies have consistently resisted the
incorporation into U.S. law of such burdensome requirements charging they are "job
killers," and pointing out that a corporate inventor's job is to innovate. 171 Under this
theory, the innovators' compensation for invention is included in their paycheck.

J. Novelty Rules Differ in China and the United States, but will be Aligned Under A1A
The standards of novelty in China and the United States are currently different
but will become similar when certain provisions of the AIA become effective. China
currently has a rule of absolute novelty based on world-wide publication or public use
prior to the application date. 1 72 The same criteria will be adopted by the United
States in 2013.173
Public use and sale are grounds of rejection in the United States, at the present
time, only when the use or sale takes place in the United States. 174 Upon the change
in 2013, a use or sale anywhere in the world will be patent defeating, making the
rules on public use/sale similar in both the United States and China. In both

167Chinese Patent Law, supra note 4, art. 16 ("The entity that is granted a patent right shall
award to the inventor or creator of a service invention-creation a reward and, upon exploitation of
the patented invention-creation, shall pay the inventor or creator a reasonable remuneration based
on the extent of spreading and application and the economic benefits yielded.").
16 8
JOACHIM FELDGES & BIRGIT KRAMER, BUSINESS LAWS OF GERMANY § 13:36 (Thompson
Reuters 2010) ("If the employer claims the invention, the employee is entitled to remuneration.").
189 Chinese Patent Law, supra note 4, art. 16.
170See Implementing Regulations, supra note 5, arts. 76-78.
171Vai Jo Lo, Employee Inventions and Works for Hire in Japan: A Comparative Study Against
the U.S., Chinese, and German Systems, 16 TEMP. INT'L & COMP. L.J. 279, 291-92 (2002) ("In the
event of dispute, courts have generally interpreted invention assignment contracts in favor of the
employer."); see also Cubic Corp. v. Marty, 185 Cal. App. 3d 438, 457 (Cal. App. 4th Dist. 1986)
(enforcing a contract giving patent rights to the employer).
172Chinese Patent Law, supra note 4, art. 22.
173AIA § 3(b) (to be codified at 35 U.S.C. § 102).
17435 U.S.C. § 102(b) (2006) ("A person shall be entitled to a patent unless .. ,. the invention
was . . . in public use or on sale in this country, more than one year prior to the date of the
application for patent in the United States. .. )
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countries, there will be limited grace periods during which the inventor can publish.
In either country, the grace period regulations must be carefully examined. 175
Also, while the USPTO may reject an application based on prior publications
anywhere in the world, under the so called Hilmer rule, a patent which claims
priority to a non-U.S. patent application is not a reference against a U.S. patent
application until the date that the reference application is actually filed in the
USPTO. 176 In 2013, that will change and a U.S. patent or application which claims
priority in a non-U.S. application can be applied as prior art as of the non-U.S. filing
date (priority date) of the foreign application, again establishing concordance
between U.S. and Chinese law. 177 Finally, the current law in the United States
allows a general, one year grace period before a statutory bar comes into effect. 178
Once the 2013 provisions come into play, the grace period will be limited to the
inventor's activity. 179
There will still remain some other subtle differences on issues of novelty,
including what constitutes an anticipating disclosure and the length of grace periods
that may be applicable, so concerned persons should consult a Chinese or U.S. patent
attorney to determine novelty prior to filing.

K. Non-Obvious Subject Matter is Required in the United States and China
In order to sustain the validity of an "invention" or regular patent in the United
States and China, the claimed invention must be an advance over the prior art that
is both novel and non-obvious. Terms of art such as "inventive step" and "height of
invention" are often used to describe the necessary inventive element in China. 180
Chinese Law defines "inventiveness" as "compared with technology existing before
the date of application the invention has prominent substantive features and
represents a notable progress." 181 Existing technology refers to prior technology on a
worldwide basis. 182
In the United States, the subject matter of an invention sought to be patented
must be non-obvious viewed as a whole under Graham v. John Deere, 1 83 as further

175Chinese Patent Law, supra note 4, art. 24.
176 In re Hilmer, 359 F.2d 859, 877 (C.C.P.A. 1966).
177AIA, at § 3(b) (to be codified at 35 U.S.C. § 102).
178 35 U.S.C. § 102(b) (2006) (stating no patent shall issue if it was described or patented "more
than one year prior to the date of the application for patent in the United States.").
179 AIA, at § 3(b) (to be codified at 35 U.S.C. § 102).
180 Yi-Chen Su, What About Know-How: Heightened Obviousness and Lowered Disclosure is
Not a Panacea to the American Patent System for Biotechnology Medication and Pharmaceutical
Inventions in the Post-KSR Era, 14 MARQ. INTELL. PROP. L. REV. 321, 349 (2010) ("[T]he Chinese

patent system has generally adopted the European problem-and-solution approach in determining

obviousness."l).

181Chinese Patent Law, supra note 4, art. 22.
182 Id. art. 30.
183Graham v. John Deere Co., 383 U.S. 1, 15 (1966) ("If this difference is such that the subject
matter as a whole would have been obvious at the time to a person skilled in the art, then the
subject matter cannot be patented.").
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determined in the recent U.S. Supreme Court ruling of KSR v Teleflex. 184
Patentability cannot be negated by the manner in which the invention was made. 185
This sentence was added to the U.S. Code in recognition of the fact that, in modern
corporate research, several scientists might make serial innovations from a known
starting point where each of the several changes might be obvious from each other. 186
However, the obviousness standard requires that the examiner look at the prior art
at the starting point versus the final invention, that is look at the invention as a
whole. 187 If that is not obvious from the prior art then the subject matter is
patentable in the United States.

L. Business Methods are Patentable in the United States, while a Three Part Technical
Test is Applied in China to Assess Patentability.
Transactions, such as those related to games, gambling, and banking processes,
may be patentable in the United States as so called "business method patents" if
properly tied to a machine or apparatus. In Bilski v. Kappos18 8 the Supreme Court
affirmed the decision of the Court of Appeals for the Federal Circuit that Bilski's
application did not contain patentable subject matter since the calculation method
was not tied to a machine or apparatus, nor did it transform an article into a
different state or thing. However, the Supreme Court reversed the Federal Circuit's
holding that the machine or transformation tests are the sole tests of patentable
subject matter, especially in this information age. 1 89 Over the past decade, China's
stance has evolved to reluctant acceptance of "business methods" if they satisfy a
three part test whereby a technical solution uses technical means to achieve a
technical result, provided they are supported in the original disclosure. 190 However,
the three-step business transaction method described in the Bilski case would not be
patentable in China even if tied to a machine. Yet appropriate business method

184KSR Int'l Co. v. Teleflex Inc., 550 U.S. 398, 405 (2007).
185 35 U.S.C. § 103(a) (2006).
186Carter-Wallace, Inc. v. Gillette Co., 675 F.2d 10, 14 (1st Cir. 1982). This sentence was
inserted into the statute because the Senate wanted to reverse the test: "That is to say, the new
device, however useful it may be, must reveal the flash of creative genius, not merely the skill of the
calling. If it fails, it has not established its right to a private grant on the public domain." Id.;
Graham, 383 U.S. at 16 n.8 (stating "it is immaterial whether [the patent] resulted from long toil
and experimentation or from a flash of genius.").
187 35 U.S.C. § 103(a).
188 Bilski v. Kappos, 130 S.Ct. 3218, 3229 (2010).
189 Id. at 3231 ("In disapproving an exclusive machine-or-transformation test, we by no means
foreclose the Federal Circuit's development of other limiting criteria that further the purposes of the
Patent Act and are nut inconsistent with its text.").
190 Principlesof Examining Business Method PatentApplication, IPR IN CHINA (June 20, 2008),
http://www.chinaipr.gov.cn/guidespatentarticle/guides/agparent/agpguidance/200806/241 156_1.html;
Steve Song & Guowei Liu, Patent Eligibility of Business Method in China from the U.S. Perspective,
1
CHINA
PAT.
&
TRADEMARKS
54,
55
(2011),
available
at
http://www.cpt.cn/uploadfiles/20110107112430782.Pdf.
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inventions may be patentable if the application and claims are carefully structured
from the beginning by specialized Chinese patent attorneys. 191

M. China has Compulsory License Provisions which are Strongly Opposed in the
United States
U.S. law provides that patentees have the right to exclude others from using
their patented subject matter for the full term of the patent. 192 China, on the other
hand, passed a provision in the 2008 amendments that permits compulsory licensing
in certain circumstances. 193 An application for compulsory licensing can be made
three years after grant or four years after filing, or if China deems the patentee's acts
result in a monopoly. 194 Article 51 of C.P.L. deals with the right to request a
compulsory license in order for a later inventor to practice an improvement that is
otherwise blocked by an earlier broadly claimed invention. 1 95
Semi-conductor
inventions are specifically mentioned in C.P.L. article 52 which specifies the
circumstances where such a patent may be subject to compulsory licensing. 1 96
Chinese law states that the compulsory license is for the domestic Chinese market
unless otherwise prescribed. 197 These provisions are of concern to the United States
and global manufacturers. For example pharmaceutical and semiconductor makers
fear that China will declare their position a monopoly and require a compulsory
license of the patent. 1 98 Compulsory licensing of intellectual property like the taking
of real property under eminent domain is always ripe for abuse to the detriment of
the property holder.

N. A1A Provides Meaningful Prior User Rights in the United States for the First Time
While China and most countries of the world have had prior user rights in their
laws for many years, the U.S. Congress has steadfastly opposed including prior user
rights up to the time of AIA. However, the harmonization changes of AIA seem to
require that Congress finally provide some protection for manufacturers who invest
in a process of making a product and are accused of infringement based on a later
invented patent. Under current law, an infringing manufacturer can be held liable

191 Zheng Lizhu & Kenneth Y. Choy, The Impact of Bilski on Business Method Patent, KING &
WOOD (Feb. 2009), http://www.kingandwood.com/article.aspx?id=The-Impact-of-Bilski-on-BusinessMethod-Patent&language=en.
192 Waterman v. Mackenzie, 138 U.S. 252, 255 (1891) (stating that a patent grants the patentee
the "exclusive right to make, use, and vend the invention or discovery throughout the United
States").
193 See Chinese Patent Law, supra note 4, arts. 48-51.
194 Id. art. 48.
195 Id. art. 51.
196 Id. art. 52.
197 Id. arts. 48, 50, 53.
198 See J. Benjamin Bai et al., What Does the Third Amendment to China's Patent Law Mean to
You?, 21 INT'L Q. 2, 2 (2009).
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for infringement and his operation may be enjoined from further processing unless he
can prove that his process was open to the public for more than one year prior to the
patent application date. 199 Since most manufacturers restrict access to their facilities
which are often deemed to be secret operations there is often no adequate defense to
protect domestic investment. 200 AIA provides that such a prior use whether secret or
not is subject to a prior user defense and may continue to operate. 201 The prior user
right arises only if the prior use took place continuously from one year prior to the
date of the patent application. 202
Congress did not include "substantial preparations" for manufacturing as a
defense and there are other fine points that may need adjustment in future patent
reform.203 Premarket activity for regulatory review such as for drug products gives
rise to the prior user defense. 204 The defense cannot be asserted against University
owned patents, however. 205
The prior use defense is a personal defense that must be asserted by the parties
who gave rise to the defense or their successors in interest. 206 The patent that is
asserted is not invalidated as a result of the prior user defense and hence is not of
benefit to others. 207 In addition this defense is specific to the site that gave rise to
the prior use. 208 Whether the original plant may be expanded in capacity on the
same site is an open question.
Article 69 of the C.P.L. states the basic prior user rights for patents applicable in
China. 209 It is not an infringement if the accused has, before the effective date of the
application for patent, continuously used the process or product. 210 The Chinese law
specifies that the continued use shall be of the same scope. 211 This provision is in line
with prior user provisions in other countries and may restrict expansion of plant
capacity.

0. Security Reviews Differ in China Versus the United States
China recently changed its approach to examining applications for international
patents where the invention was made in China. Prior to 2009, a Chinese applicant
for an invention made in China was required to first file the application in China
19935 U.S.C. § 273(a)(2)(B) (2006).
200 U.S. PAT. & TRADEMARK OFF., REPORT ON THE PRIOR USER RIGHTS DEFENSE 7 (Jan. 2012)
[hereinafter PRIOR USER RIGHTS] (describing how prior to AIA, a manufacturer who invents a
manufacturing process, but does not disclose it, would now have a potential defense against an
infringement suit by a later patent applicant).
201 AIA, § 5(a) (to be codified at 35 U.S.C. § 273(a)).
202 Id.
203 See id.
204 Id. (to be codified at 35 U.S.C.§ 273(c)(1)).
205 Id. (to be codified at 35 U.S.C. § 273(e)(5)(A)).
206 Id. (to be codified at 35 U.S.C. § 273(e)(1)(A)).
207 Id. (to be codified at 35 U.S.C. § 273(g)).
208 Id. (to be codified at 35 U.S.C. § 273(e)(1)(C)).
209 Chinese Patent Law, supra note 4, art. 69.
2
10 1d
211

Id.
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before filing elsewhere. 212 Now, like U.S. law, any application that is to be filed
abroad must first go through a national security examination.2 1 3 Such a security
examination can take several months. 2 14 Authorities in China may use the initial
four month period to object to foreign filing, and may take up to six months to make a
final denial of foreign filing. 21 5
Unlike China, however, an invention made in the U.S. can be foreign filed
within several days based on an expedited petition for a license. 216 We are not aware
of any provision for expedited clearance in SIPO.

P. China's Employment Laws Govern some Trade Secret and Non-Compete Issues
ConcerningIntellectual Property
Not all intellectual property-related provisions are contained in China's patent
laws. One must also look to China's employment laws, which were also amended and
revamped in 2008.217
Several features of these laws are quite different from
American practice. The new employment contract law in China clarifies that, in
order to enforce a non-compete clause, there must be provided post-termination
compensation for the period during which the non-compete restriction remains
effective. 218 In the United States, non-compete laws are governed by each state and
we are not aware of any state which requires post termination compensation to
support a non-compete provision. 219 Another surprise in Chinese law is the
restriction on the personnel who can be subject to confidentiality provisions. Only
technical and managerial personnel are generally eligible. In addition, trade secret
litigation cases in China indicate that special compensation may be paid to
employees who are required to maintain secrets. 220 This is often accomplished by
showing that a part of the overall pay of an employee, e.g., five percent, is allocated to
maintaining trade secrets during employment and after termination.

Id. art. 20.
213 Compare id. (describing China's State security examination requirement), with 35
U.S.C.§ 184 (2006) (describing the process for filing a patent application in a foreign country which
states that any application is subject to a national security review under section 181).
212

214

SIPO, GENERAL INTRODUCTION TO THE THIRD REVISION OF THE PATENT LAW OF THE

PEOPLE'S REPUBLIC OF CHINA AND ITS IMPLEMENTING REGULATIONS
http://english.sipo.gov.cn/laws/lawsregulations/201012/t20101210_553631.html
timeline for notification and decisions of State security examinations).
2

3 (Dec. 10, 2010,
(describing
the

151d4

37 C.F.R. § 5.12 (2010); 35 U.S.C. § 184.
217 Labor Contract Law of the People's Republic of China (promulgated by the Standing
Comm'n
Nat'1 People's Cong., June 29, 2007, effective Jan. 1, 2008) arts. 23-24.
2
216

18Id.

10-265 LABOR AND EMPLOYMENT LAW § 265.01 (Matthew Bender & Co. 2011) (stating that
enforcement of restrictive covenants varies from state to state).
220 Chen Danhong & You Yunting, Shall It be Companies' Obligation to Pay Employees
Confidentiality Remuneration by China Laws?, BRIDGE IP LAW COMMENTARY (Feb. 17, 2012),
http://www.chinaiplawyer.com/companies-obligation-pay-employees-confidentiality-remunerationchina-laws-2/.
219
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III. WHAT DOES AIA PORTEND FOR THE FUTURE?
The remaining sections of this article discuss some significant changes to U.S.
law introduced by AIA and comment on Chinese practice if there is a corresponding
provision.

A. Grace Periods have been Altered, Increasingthe Risk of CommercializationPrior to
Filing a Patent
AIA significantly changes the nature of grace periods applicable to prior art.
Under current law effective up to March 16, 2013, inventors enjoy full protection
against disclosures, public use and sales that occurred within one year of filing an
application, regardless of who made the disclosure. 221 Under AIA, any printed
publication, public use or sale, even one day prior to the application's filing date, can
be an effective reference against a patent application.22 2 Section 102, however, is
amended by AIA to provide a limited grace period of one year for disclosure obtained
directly or indirectly from the inventors. 223
Many aspects of commercial development in the U.S. have relied on the general
one year grace period rooted in American law which permitted intercompany
activities such as testing prior to filing patent applications. 224 It can be argued that,
under AIA changes, patent protection for many of these inventions will be lost to the
detriment of American commerce.
A circumstance of wide application is where an inventor associated with a
Company A in the U.S., for example, reduces to practice in his laboratory a novel
anti-corrosion paint composition that shows promise in the small scale testing, but
requires a larger scale test only available at an automotive Company B nearby. The
inventor discloses the invention to Company A that discloses the information to
Company B. Additional tests at Company B reveal numerous new uses for the
composition and confirm those disclosed. Company B provides a full report back to
Company A where Company A then files a patent application on the inventions and
all this activity takes place within one year.
Under existing law there should be no question that a patent granted on
Company A's application could not be invalidated based on these disclosures since an
unrestricted grace period of one year applies.
However, Congress has added
language in AIA to restrict the terms and conditions under which the one year grace
period applies. What is meant by disclosures directly or indirectly from the inventor
will have to be construed by the courts when a defense is asserted. 225 The answer is
35 U.S.C. § 102(b) (2006).
§ 3(b) (to be codified at 35 U.S.C. § 273(a)(1)).
223 Id.
224 See Todd McCracken, Patent Reform Bill Hurts Small Business, 18 WESTLAW J. INTELL.
PROP. 1, 2 (2012).
225 See James Yang, First Inventor to File System Under the America Invents Act, OC PATENT
LAWYER (Oct. 21, 2011), http://ocpatentlawyer.com/first-inventor-to-file-system-under-the-americainvents-act! (describing the potential for various interpretations of disclosure that will need to be
decided by litigation).
221

222 AIA,
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not as simple as always file on any invention prior to disclosure for testing at another
organization since many commercial organizations make numerous inventions such
as the new paint composition referenced above and wish to send the samples out for
larger scale or different testing. It is very expensive to file them all prior to
sampling. This issue will have to be answered by counsel for each organization that
engages in such activities as the risk assessment will be highly fact sensitive.

B. AA Narrows the Application of Certain Other Types of PriorArt Benefiting
Commerce
On the other side of the coin, the AIA removes certain patents and applications
as references under section 102(a)(2) where the subject matter was developed under a
joint research agreement. 226 It also renders inapplicable as references certain
commonly owned or assigned applications or patents. 227 These changes remove
certain barriers to patent coverage of inventions made under commercial joint
development agreements and commonly assigned subject matter, and will result in
expanded patent coverage of new technology. 228 The authors are not aware of
corresponding provisions in Chinese law.
One important change is the requirement of common ownership is no longer
required at the time the invention was made. A reference may be removed by a later
merger of interests between the current applicant and the reference applicant. 229

C. New Misjoinder Provisions of the A1A
The amended law in section 299 of the U.S. Patent Act codifies that accused
infringers may be joined in one action where:
*

The right to relief is asserted against the parties jointly, severally or
alternative liability;

*

The cause arises out of the same transaction or occurrence or series of
such;

*

Accuses the same product or process;

*

Alleging that the defendants infringe the same patent is insufficient
ground for joinder. 230

226 AIA, § 3(b) (to be codified at 35 U.S.C § 102(c)).
227 Id. (to be codified at 35 U.S.C. § 102(b)(2)).
228 PRIOR USER RIGHTS, supra note 200 (describing how section 273 will expand to cover all
technologies).
229 Id.
230 35 U.S.C. § 299.
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Litigation by non-practicing entity firms, commonly called trolls, has been
steadily on the rise for the past several years. 231 A common troll practice has been to
name as many defendants as possible who infringe the same patent in popular
jurisdictions such as Delaware or the Eastern District of Texas. 232 This practice is
substantially curtailed by this new law where products and transactions are different
even though the same patent might be infringed. The result of this change is not
likely to deter trolls from bringing suits against infringers, although the cost of
separate suits could be a deterrent; and different district courts will be faced with the
task of claim construction of the same claims that are being interpreted in one or
more other districts. 233 Variable interpretations of the same claim may or may not be
corrected at the Court of Appeals for the Federal Circuit

D. Under AM, Novelty will be Defeated by InternationalPublic Use or Sale
Use or sale anywhere in the world will be novelty defeating beginning March 16,
2013 when the relevant provisions of AIA take effect. 234 This might significantly
increase the risk of capitalizing certain innovations of global interest. 235 Yet this
provision is part of the global patent harmonization package.

E. Unlike Interference Proceedings, Derivation Proceedings will Survive Under A1A
Interferences will be phased out as noted above. 236 A slim vestige will remain,
however, in the form of derivation proceedings where the inventor of a later filed
application attempts to prove that the inventor of an earlier filed application derived
the claimed invention from him. 237 The proceedings are initiated once the second
inventor learns of the derived claims from publication of the first application and
files a petition, and the derivation claim must be filed within one year period

231Joe Beyers, Perspective, Rise of the Patent Trolls, CNET NEWS (Oct. 12, 2005),
http://news.cnet.com/Rise-of-the-patent-trolls/2010-1071_3-5892996.html.
232 Stijepko Tokic, The Role of Consumers in Deterring Settlement Agreements Based on Invalid
Patents: The Case of Non-Practicing Entities, 2012 STAN. TECH. L. REV. 2, 9 (2012) (describing how
non practicing entities will dilute costs by suing multiple defendants); J. Jason Williams et al.,
Strategies for Combating Patent Trolls, 17 J. INTELL. PROP. L. 367, 368 (2012) (stating that the
Eastern District of Texas and the District of Delaware are among the most popular, and most
favorable, jurisdictions used by non-practicing entity firms).
233 Erick Robinson, New Patent Reform Law Could Reduce Lawsuits by Non-practicingEntities,
OPENSOURCE.COM (Sept. 16, 2011), http://opensource.com/1aw/1 1/9/new-patent-reform-law-couldreduce-lawsuits-non-practicing-entity (describing how the new joinder rules could make litigation by
non-practicing entities potentially cost prohibited).
234 AIA, § 3(b)(1) (to be codified at 35 U.S.C.§ 102(a)).
235 McCracken, supra note 224, at 3.
236 See supra Part I.C. (describing how AIA changes the U.S. from a first-to-invent system to a
first-to-file system and "relegates such interferences and the accompanying case law to the annals of
history.").
237 AIA, § 3(i) (to be codified at 35 U.S.C. § 135(a)).
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beginning on date of that publication. 238 These proceeding will be adjudicated by the
newly constituted Patent Trial and Appeals Board.239

F. A1A Preserves Patent Term Extension Provisions
Key features of U.S. patent law that have no counterpart in China are the
provisions permitting extension of patent terms for pharmaceutical and other
technologies in consideration of delays in processing these patents in the USPTO. 240
The patent extension provisions for pharmaceuticals enable drug companies to
recoup the enormous investments in development and testing of drug products in the
U.S. markets. 241 However, those advantages are compromised in China where no
provision is made for extension of patents for any reason.242 As China begins to
develop its own proprietary drug products it is likely China will recognize the need to
provide extended coverage. 243

G. Qui Tam and Marking Changes in A1A
Congress used the new patent law as an opportunity to reverse a strong tide of
qui tam actions for false patent marking. Under the former version of the false
marking statute, anyone could bring suit on behalf of the United States for the
marking of a patent that did not cover the marked device for the purpose of deceiving
the public. 244 The remedy for such an action was a fine of up to $500 per offense, to
be split with the United States government. 245 The 2009 Federal Circuit decision in
Forest Group, Inc. v. Bon Tool Co. 246 created a "cottage industry" of false marking
plaintiffs and led to the filing of hundreds of false marking cases over the course of a
year. The Court held that the $500 fine could be assessed on a per article basis,
rather than per decision to mark, thus increasing dramatically the potential windfall
to a false marking plaintiff.247
While the Federal Circuit took the first step in curbing the onslaught of false
marking suits by holding that such actions were subject to the heightened pleading
238

Id.

239

Id. (to be codified at 35 U.S.C. § 135(b)).

37 C.F.R. § 1.710 (2010); 35 U.S.C. §§ 155, 156.
35 U.S.C.§ 156(c) (explaining that the Hatch-Waxman Act allows manufacturers to extend
patent exclusivity to a maximum of five years).
242 Bai, supra note 198, at 5 ("In addition, China does not afford patent term extension or
patent term restoration, to compensate for regulatory delays in obtaining State Food and Drug
Administration approval of drugs.").
243 Jeffrey A. Andrews, Pfizer's Viagra Patent and the Promise of Patent Protection in China, 28
LOY. L.A. INT'L & COMP. L. REV. 1, 9 (2006) ("With increasing profits and opportunity at stake, the
Chinese drug companies that once built businesses around pirating foreign-owned pharmaceuticals
are now beginning to use intellectual property laws as a strategic tool.").
244 35 U.S.C § 292(a) (2006).
245 Id. § 292(b).
246 FOrest Grp., Inc. v. Bon Tool Co., 590 F.3d 1295 (Fed. Cir. 2009).
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requirements of Rule 9(b) of the Federal Rules of Civil Procedure,248 the ultimate
death knell was sounded by Congress in AIA. The amended version of section 292
effectively eradicates these suits by removing the qui tam action.24 9 With the
amendment, the United States can still bring suit for the $500 fine, but private
parties are limited to recovering damages based on a competitive injury suffered as a
result of the false marking. 250 Also, the amendment clarifies that the marking of an
expired patent that once covered the marked device is no longer considered a false
marking. 251 The amendments to section 292 are retroactive, and apply to false
marking cases pending or filed on or after the date of enactment of AIA. 252
Despite challenges to the constitutionality of the retroactive removal of the qui
tam action by some of the plaintiffs affected, it is clear that the scope and number of
false marking cases going forward will be drastically reduced. 253 It remains to be
seen whether the United States has the desire or the resources to continue any of the
existing suits, or how often the government will use its ability to bring suits under
the statute. Either way, AIA marks the end of false marking litigation as a viable
business model.
AIA also makes the marking of patented products for the purpose of providing
notice of patent protection easier. Section 287 prior to the new patent law allowed for
the marking of a patented device with the word "patent" or the abbreviation "pat."
with patent numbers covering that product. 254 In the event that it was impractical to
mark the product directly, the statute also allowed for the affixing of a label to the
packaging for that product. 255 The benefit of marking a product was the ability to
obtain damages for patent infringement without having to show actual notice of the
patent prior to the filing of a patent infringement suit. 256
Section 287 as amended in AIA allows for the marking of "patent" or "pat."
followed by an address for a website containing a listing of patent numbers that cover
the device. 257 The website must be free to access. 258 Like the amendments to the
false marking section, the amendment allowing for virtual marking is retroactive. 259
This change in the law of marking will make it easier to maintain an up-to-date
listing of patents in force that read on a marketed device. It will also potentially
In re BP Lubricants USA, Inc., 637 F.3d 1307 (Fed. Cir. 2011).
AIA § 16(b) (to be codified at 35 U.S.C. § 292); Jefferson Perkins, Patent Law Change: A
First Look at the America Invents Act, 24 DCBA BRIEF 30, 33 (2012) ("The new Act abolishes the qui
tam action.").
250 AIA § 16(b)(1)-(2) (to be codified at 35 U.S.C. § 292(a)-(b)); Perkins, supra note 249, at 33
("A party may recover for false marking only if it can prove "competitive injury").
251 AIA § 16(b)(3) (to be codified at 35 U.S.C. § 292(c)).
252 Id. § 16(b)(2)(4) (to be codified 35 U.S.C. § 292(b))
253 Shivan Mehta, Patent Reform Act of 2010: The Time for Change Is Now, 7 OKLA. J.L. &
TECH. 56, 56 (2011) ("It seems apparent that the courts will benefit greatly by a reduction of false
marking litigation due to an increased burden upon the plaintiff to prove that he or she sustained a
"competitive injury.").
254 35 U..
§ 287(a) (2006).
255 Id.
256 Id.
257 AIA, § 16(a)(1) (to be codified at 35 U.S.C. § 287).
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allow for a more cost effective means of changing a patent marking, particularly in
the situation where the marking is made using a mold, as it will enable monitoring of
a patent listing without undergoing the expense of changing the mold.

H. New Post Grant Proceedings in the United States
The introduction of post-grant review or an "opposition" procedure immediately
on grant of a U.S. patent and up to nine months thereafter is a significant change in
U.S. patent law. 260 In the past, interferences have served this purpose among others,
however, the opposition can be filed by any adverse party whereas standing in an
interference action was limited to those having a conflicting application. 261
Interferences took "forever" to be concluded whereas the hope is that invalid claims
can be relatively quickly adjudicated or settled among the parties in P.G.R. 262 If this
notion is realized, then P.G.R. and its companion inter partes review (I.P.R.) will be a
boon to commercialization and job creation. For this reason this article concludes
with an outline of what is known of the new process.
Post grant review may be initiated by a petition from an adverse party seeking
to invalidate a patent granted on or after the effective date. 263 The threshold for
initiation of P.G.R. is a showing in the petition that one or more of the patent's claims
is likely to be held invalid. 264 Prior art references and other evidence of invalidity
must accompany the petition. 265
The petitioner must identify all parties in
interest. 266
Any ground of invalidity can be raised under section 282(b)(2). 267 These grounds
include conditions of patentability set forth in sections 101 through 103 which are
fair game for P.G.R. Thus, grounds of invalidity that can be raised in PGR include
lack of patent eligible subject matter under section 101, prior public use or sale under
section 102, prior publication under section 102, obviousness under section 103 and

AIA § 6(d) (to be codified at 35 U.S.C. § 321).
261William Ahmann & Tenaya Rodewald, Patent Reform: The Impact On Start-Ups, 24
INTELL. PROP. & TECH. L.J. 3, 4 (2012) ("In an interference proceeding, a board at the [USPTO] or a
federal court determines whether the party that was first to file (the senior party) or the party that
was allegedly first to invent (the junior party) was entitled to a patent."); David Herrington et al.,
Congress Makes Substantial Changes to Patent Law with the America Invents Act, 23 INTELL. PROP.
& TECH. L.J. 3, 5 (2011) ("The Reform Act creates an entirely new post-grant review procedure,
allowing anyone other than the patent owner to challenge the validity of a newly granted or reissued
patent, on essentially any statutory grounds.").
262 See Ahmann, supra note 261, at 4 (noting that "[i]nterferences are expensive and
complicated."); see also Herrington, supra note 261, at 5 ("Once in effect, post-grant reviews should
provide an attractive option for challenging a patent's validity: They should offer a procedure that is
more robust and wide-ranging than reexaminations under prior law yet faster and less expensive
than court challenges.").
260

263 Herrington, supra note 261, at 5.

264 Ahmann, supra note 261, at 5 (explaining that AIA allows challenges on essentially any
statutory grounds).
265 AIA § 6(d) (to be codified at 35 U.S.C § 322(a)(3)).
266 Id. (to be codified at 35 U.S.C. § 322(a)(2)).
267 Id. (to be codified at 35 U.S.C. § 32 1(b)).
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defects of enablement or lack of proper written description under sections of 112.268
Congress added an additional ground for P.G.R. that would provide jurisdiction in
the P.T.A.B. to take on important novel or unsettled question of law raised by the
case subject matter. 269
Post grant review must be initiated within nine months of patent grant. 270 Post
grant review, unlike inter partes review, only applies to patents granted on or after
the effective date of the statute, 271 whereas any granted patent can be considered
under inter partes review. 272 The I.P.R. proceedings can only be initiated after the
period for P.G.R. or until after P.G.R. is terminated. 273 The grounds of I.P.R. are
restricted to invalidity by reason of prior patents or publications under sections 102
and 103.274 Prior use and sale are not to be part of I.P.R. 275
While P.R.G. and I.P.R. are estimated to be less costly than litigation in court,
AIA includes estoppel for all grounds which are raised or could have been raised,
attorneys might be cautious about initiating these proceedings. 276 There might be a
preference for I.P.R. since the estoppel is limited to grounds based on published
materials whereas P.G.R. includes essentially all grounds of invalidity. Moreover,
the USPTO is not familiar with trials based on evidence of prior public use and sale;
hence, most litigators might prefer to have these issues adjudicated by a Federal
Court.

IV. CONCLUSION
The P.G.R. and I.P.R. sections of AIA are a good place to conclude since, like
many of the new Chinese laws, these sections in particular require implementation
regulations to be drafted and published for comment. Knotty issues remain since the
U.S. and Chinese patent statutes are outlines containing only the key features of the
laws without detailed processes and guidance.
The fees to be charged in order for the USPTO to recover its costs in conducting
P.G.R., is an example of one of the difficulties in implementing such legislation. The
USPTO is considering fees in the range from $25,000 to $50,000 for P.G.R.277 Such
hefty fees are likely to be a disincentive to use of this important new feature of the
law and the fees are likely to be opposed by the user community. Yet the new law

268 Bui, supra note 117, at 460 (explaining that P.G.R. may be based on any grounds that could
be raised under paragraphs (2) or (3) of section 282(b)).
269 AIA § 6(d) (to be codified at 35 U.S.C § 324(b)).
270 Id. (to be codified at 35 U.S.C § 321(c)).
271Id. (to be codified at 35 U.S.C § 321).
272 Id. § 6(a) (to be codified at 35 U.S.C § 311).
274

Id.

275
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Id. (to be codified at 35 U.S.C § 3 11(b)).
Id. (to be codified at 35 U.S.C § 315).

277 DEP'T OF cOM., TABLE OF PATENT FEE CHANGES, UNITED STATES PATENT AND TRADEMARK
OFFICE
3
(Feb.
7,
2012),
http://www.uspto.gov/aia implementation/fee setting_ppac hearing attachment_1-table of patent fee changes_7febl2.pdf.
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requires the USPTO to recover its costs.
There are hundreds of issues of
implementation to be addressed and the schedule is tight.
Since the devil is in the details of both Chinese and American efforts to
implement the new laws, the public interest demands that all stakeholders carefully
examine and comment as draft regulations are published. It is interesting to note
that the Chinese authorities have initiated the practice of permitting public comment
on certain intellectual property regulations and that is a good sign for the future.
China has already implemented its 2008 amendments to the patent laws by
guidelines and some judicial interpretations, whereas the U.S. is struggling to
propose implementing regulations. 278 Judicial interpretation in the U.S. will arise
from specific litigation. The authors are struck by the aggressive goal setting on the
Chinese which the Director of the USPTO described as "mind blowing." 279 However,
charges in the recent DuPont trade secret case 280 potentially linking Walter Liew, the
defendant, to the Chinese government are not helpful to the cause of peaceful
competition in the innovation race. 281 The authors will be keenly interested in
observing the interactions between the growth of innovation and the ongoing changes
needed in the laws and regulations to accommodate and promote quality patent
coverage and enforcement both in China and in the United States.
Who got it right is anyone's guess. With lots of luck, innovation, and a measure
of good faith and understanding, both China and the U.S. might find that healthy
battles in the patentable innovation race are part of a war where both sides can win.

278 Bui, supra note 117, at 441 ("The enactment of the Leahy-Smith America Invents Act
represents the success of otherwise contentious efforts by Congress and industry groups to reform
U.S. patent law since the early 2000s.").
279 See Lohr, supra note 3, at BU3.
280 See DuPont v. Kolon Indus., 637 F.3d 435, 454 (4th Cir. 2011).
281Abigail Rubenstein, Chinese Cos. Indicted Over DuPont Trade Secret Theft, LAW360 (Feb. 8,
http://www.1aw360.com/ip/articles/307807?nl pk=3657918c-3736-4fbc-89e42012),
664cdabe47e4&utm source newsletter&utm medium email&utm campaign ip.

